MEG3: an Oncogenic Long Non-coding RNA in Different Cancers

1.

Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, Cao X, Jing X, Wang X, Siddiqui J, Wei JT, Robinson D, Iyer HK, Palanisamy N, Maher CA, Chinnaiyan AM (2011) Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 29(8):742–749. https://doi.org/10.1038/nbt.1914 CrossRefPubMedPubMedCentral

2.

Ren S, Peng Z, Mao JH, Yu Y, Yin C, Gao X, Cui Z, Zhang J, Yi K, Xu W, Chen C, Wang F, Guo X, Lu J, Yang J, Wei M, Tian Z, Guan Y, Tang L, Xu C, Wang L, Gao X, Tian W, Wang J, Yang H, Wang J, Sun Y (2012) RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res 22(5):806–821. https://doi.org/10.1038/cr.2012.30 CrossRefPubMedPubMedCentral

3.

Tsai MC, Spitale RC, Chang HY (2011) Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res 71(1):3–7. https://doi.org/10.1158/0008-5472.CAN-10-2483 CrossRefPubMedPubMedCentral

4.

Huarte M, Rinn JL (2010) Large non-coding RNAs: missing links in cancer? Hum Mol Genet 19(R2):R152–R161. https://doi.org/10.1093/hmg/ddq353 CrossRefPubMedPubMedCentral

5.

Gutschner T, Diederichs S (2012) The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9(6):703–719. https://doi.org/10.4161/rna.20481 CrossRefPubMedPubMedCentral

6.

Brunner AL, Beck AH, Edris B, Sweeney RT, Zhu SX, Li R, Montgomery K, Varma S, Gilks T, Guo X, Foley JW, Witten DM, Giacomini CP, Flynn RA, Pollack JR, Tibshirani R, Chang HY, van de Rijn M, West RB (2012) Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome Biol 13(8):R75. https://doi.org/10.1186/gb-2012-13-8-r75 CrossRefPubMedPubMedCentral

7.

Martens-Uzunova ES, Bottcher R, Croce CM, Jenster G, Visakorpi T, Calin GA (2014) Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol 65(6):1140–1151. https://doi.org/10.1016/j.eururo.2013.12.003 CrossRefPubMed

8.

Schmitt AM, Chang HY (2016) Long noncoding RNAs in Cancer pathways. Cancer Cell 29(4):452–463. https://doi.org/10.1016/j.ccell.2016.03.010 CrossRefPubMedPubMedCentral

9.

Zhou Y, Zhang X, Klibanski A (2012) MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol 48(3):R45–R53. https://doi.org/10.1530/JME-12-0008 CrossRefPubMedPubMedCentral

10.

Wylie AA, Murphy SK, Orton TC, Jirtle RL (2000) Novel imprinted DLK1/GTL2 domain on human chromosome 14 contains motifs that mimic those implicated in IGF2/H19 regulation. Genome Res 10(11):1711–1718CrossRefPubMedPubMedCentral

11.

Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, Zhou Y, Klibanski A (2010) Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology 151(3):939–947. https://doi.org/10.1210/en.2009-0657 CrossRefPubMed

12.

Miyoshi N, Wagatsuma H, Wakana S, Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino T, Ishino F (2000) Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells 5(3):211–220CrossRefPubMed

13.

Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A (2003) A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 88(11):5119–5126. https://doi.org/10.1210/jc.2003-030222 CrossRefPubMed

14.

Tan MC, Widagdo J, Chau YQ, Zhu T, Wong JJ, Cheung A, Anggono V (2017) The activity-induced Long non-coding RNA Meg3 modulates AMPA receptor surface expression in primary cortical neurons. Front Cell Neurosci 11:124. https://doi.org/10.3389/fncel.2017.00124 CrossRefPubMedPubMedCentral

15.

Murphy SK, Wylie AA, Coveler KJ, Cotter PD, Papenhausen PR, Sutton VR, Shaffer LG, Jirtle RL (2003) Epigenetic detection of human chromosome 14 uniparental disomy. Hum Mutat 22(1):92–97. https://doi.org/10.1002/humu.10237 CrossRefPubMed

16.

Zhao J, Zhang X, Zhou Y, Ansell PJ, Klibanski A (2006) Cyclic AMP stimulates MEG3 gene expression in cells through a cAMP-response element (CRE) in the MEG3 proximal promoter region. Int J Biochem Cell Biol 38(10):1808–1820. https://doi.org/10.1016/j.biocel.2006.05.004 CrossRefPubMed

17.

da Rocha ST, Edwards CA, Ito M, Ogata T, Ferguson-Smith AC (2008) Genomic imprinting at the mammalian Dlk1-Dio3 domain. Trends Genet 24(6):306–316. https://doi.org/10.1016/j.tig.2008.03.011 CrossRefPubMed

18.

Benetatos L, Vartholomatos G, Hatzimichael E (2011) MEG3 imprinted gene contribution in tumorigenesis. Int J Cancer 129(4):773–779. https://doi.org/10.1002/ijc.26052 CrossRefPubMed

19.

Wallace C, Smyth DJ, Maisuria-Armer M, Walker NM, Todd JA, Clayton DG (2010) The imprinted DLK1-MEG3 gene region on chromosome 14q32.2 alters susceptibility to type 1 diabetes. Nat Genet 42(1):68–71. https://doi.org/10.1038/ng.493 CrossRefPubMed

20.

Balik V, Srovnal J, Sulla I, Kalita O, Foltanova T, Vaverka M, Hrabalek L, Hajduch M (2013) MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas. J Neuro-Oncol 112(1):1–8. https://doi.org/10.1007/s11060-012-1038-6 CrossRef

21.

Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, Ansell PJ, Zhao J, Weng C, Klibanski A (2007) Activation of p53 by MEG3 non-coding RNA. J Biol Chem 282(34):24731–24742. https://doi.org/10.1074/jbc.M702029200 CrossRefPubMed

22.

Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810):307–310. https://doi.org/10.1038/35042675 CrossRefPubMed

23.

Vegran F, Rebucci M, Chevrier S, Cadouot M, Boidot R, Lizard-Nacol S (2013) Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma. PLoS One 8(1):e55103. https://doi.org/10.1371/journal.pone.0055103 CrossRefPubMedPubMedCentral

24.

Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358(6381):15–16. https://doi.org/10.1038/358015a0 CrossRefPubMed

25.

Zilfou JT, Lowe SW (2009) Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 1(5):a001883. https://doi.org/10.1101/cshperspect.a001883 CrossRefPubMedPubMedCentral

26.

Manfredi JJ (2010) The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 24(15):1580–1589. https://doi.org/10.1101/gad.1941710 CrossRefPubMedPubMedCentral

27.

Yee KS, Vousden KH (2005) Complicating the complexity of p53. Carcinogenesis 26(8):1317–1322. https://doi.org/10.1093/carcin/bgi122 CrossRefPubMed

28.

Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9(5):402–412. https://doi.org/10.1038/nrm2395 CrossRefPubMed

29.

Green DR, Kroemer G (2009) Cytoplasmic functions of the tumour suppressor p53. Nature 458(7242):1127–1130. https://doi.org/10.1038/nature07986 CrossRefPubMedPubMedCentral

30.

Haupt S, Haupt Y (2017) P53 at the start of the 21st century: lessons from elephants. F1000Res 6:2041. https://doi.org/10.12688/f1000research.12682.1 CrossRefPubMedPubMedCentral

31.

Hu D, Su C, Jiang M, Shen Y, Shi A, Zhao F, Chen R, Shen Z, Bao J, Tang W (2016) Fenofibrate inhibited pancreatic cancer cells proliferation via activation of p53 mediated by upregulation of LncRNA MEG3. Biochem Biophys Res Commun 471(2):290–295. https://doi.org/10.1016/j.bbrc.2016.01.169 CrossRefPubMed

32.

Liu G, Chen X (2006) Regulation of the p53 transcriptional activity. J Cell Biochem 97(3):448–458. https://doi.org/10.1002/jcb.20700 CrossRefPubMed

33.

Meek DW, Anderson CW (2009) Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 1(6):a000950. https://doi.org/10.1101/cshperspect.a000950 CrossRefPubMedPubMedCentral

34.

Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137(4):609–622. https://doi.org/10.1016/j.cell.2009.04.050 CrossRefPubMedPubMedCentral

35.

Lee JT, Gu W (2010) The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 17(1):86–92. https://doi.org/10.1038/cdd.2009.77 CrossRefPubMed

36.

Zhu J, Liu S, Ye F, Shen Y, Tie Y, Zhu J, Wei L, Jin Y, Fu H, Wu Y, Zheng X (2015) Long noncoding RNA MEG3 interacts with p53 protein and regulates partial p53 target genes in hepatoma cells. PLoS One 10(10):e0139790. https://doi.org/10.1371/journal.pone.0139790 CrossRefPubMedPubMedCentral

37.

Banerjee S, Kumar BR, Kundu TK (2004) General transcriptional coactivator PC4 activates p53 function. Mol Cell Biol 24(5):2052–2062CrossRefPubMedPubMedCentral

38.

Li N, Richard S (2016) Sam68 functions as a transcriptional coactivator of the p53 tumor suppressor. Nucleic Acids Res 44(18):8726–8741. https://doi.org/10.1093/nar/gkw582 CrossRefPubMedPubMedCentral

39.

Chene P (2001) The role of tetramerization in p53 function. Oncogene 20(21):2611–2617. https://doi.org/10.1038/sj.onc.1204373 CrossRefPubMed

40.

Follis AV, Llambi F, Ou L, Baran K, Green DR, Kriwacki RW (2014) The DNA-binding domain mediates both nuclear and cytosolic functions of p53. Nat Struct Mol Biol 21(6):535–543. https://doi.org/10.1038/nsmb.2829 CrossRefPubMedPubMedCentral

41.

Joerger AC, Fersht AR (2007) Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26(15):2226–2242. https://doi.org/10.1038/sj.onc.1210291 CrossRefPubMed

42.

Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622–629. https://doi.org/10.1002/humu.20495 CrossRefPubMed

43.

Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88(3):323–331CrossRefPubMed

44.

Huang SS, Huang JS (2005) TGF-beta control of cell proliferation. J Cell Biochem 96(3):447–462. https://doi.org/10.1002/jcb.20558 CrossRefPubMed

45.

Corre J, Hebraud B, Bourin P (2013) Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med 2(12):946–952. https://doi.org/10.5966/sctm.2013-0055 CrossRefPubMedPubMedCentral

46.

Wang P, Chen D, Ma H, Li Y (2017) Long non-coding RNA MEG3 regulates proliferation and apoptosis in non-small cell lung cancer via the miR-205-5p/LRP1 pathway. RSC Adv 7(78):49710–49719CrossRef

47.

Shi Y, Lv C, Shi L, Tu G (2018) MEG3 inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells. Oncol Lett 15(2):1917–1923. https://doi.org/10.3892/ol.2017.7463 CrossRefPubMed

48.

Lyu Y, Lou J, Yang Y, Feng J, Hao Y, Huang S, Yin L, Xu J, Huang D, Ma B, Zou D, Wang Y, Zhang Y, Zhang B, Chen P, Yu K, Lam EW, Wang X, Liu Q, Yan J, Jin B (2017) Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways. Leukemia 31(12):2543–2551. https://doi.org/10.1038/leu.2017.116 CrossRefPubMedPubMedCentral

49.

Giacinti C, Giordano A (2006) RB and cell cycle progression. Oncogene 25(38):5220–5227. https://doi.org/10.1038/sj.onc.1209615 CrossRefPubMed

50.

Zhang Z, Li M, Wang H, Agrawal S, Zhang R (2003) Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A 100(20):11636–11641. https://doi.org/10.1073/pnas.1934692100 CrossRefPubMedPubMedCentral

51.

Al-Khalaf HH, Lach B, Allam A, Hassounah M, Alkhani A, Elkum N, Alrokayan SA, Aboussekhra A (2008) Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res 1188:25–34. https://doi.org/10.1016/j.brainres.2007.10.074 CrossRefPubMed

52.

He Y, Luo Y, Liang B, Ye L, Lu G, He W (2017) Potential applications of MEG3 in cancer diagnosis and prognosis. Oncotarget 8(42):73282–73295. https://doi.org/10.18632/oncotarget.19931 CrossRefPubMedPubMedCentral

53.

Kumar MM, Goyal R (2017) LncRNA as a therapeutic target for angiogenesis. Curr Top Med Chem 17(15):1750–1757. https://doi.org/10.2174/1568026617666161116144744 CrossRefPubMedPubMedCentral

54.

Li CY, Shan S, Huang Q, Braun RD, Lanzen J, Hu K, Lin P, Dewhirst MW (2000) Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92(2):143–147CrossRefPubMed

55.

Johnson KE, Wilgus TA (2014) Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care (New Rochelle) 3(10):647–661. https://doi.org/10.1089/wound.2013.0517 CrossRefPubMedCentral

56.

Lee SH, Lee S, Yang H, Song S, Kim K, Saunders TL, Yoon JK, Koh GY, Kim I (2014) Notch pathway targets proangiogenic regulator Sox17 to restrict angiogenesis. Circ Res 115(2):215–226. https://doi.org/10.1161/CIRCRESAHA.115.303142 CrossRefPubMed

57.

Zhan R, Xu K, Pan J, Xu Q, Xu S, Shen J (2017) Long noncoding RNA MEG3 mediated angiogenesis after cerebral infarction through regulating p53/NOX4 axis. Biochem Biophys Res Commun 490(3):700–706. https://doi.org/10.1016/j.bbrc.2017.06.104 CrossRefPubMed

58.

Gordon FE, Nutt CL, Cheunsuchon P, Nakayama Y, Provencher KA, Rice KA, Zhou Y, Zhang X, Klibanski A (2010) Increased expression of angiogenic genes in the brains of mouse meg3-null embryos. Endocrinology 151(6):2443–2452. https://doi.org/10.1210/en.2009-1151 CrossRefPubMedPubMedCentral

59.

Su W, Xie W, Shang Q, Su B (2015) The Long noncoding RNA MEG3 is downregulated and inversely associated with VEGF levels in osteoarthritis. Biomed Res Int 2015:356893. https://doi.org/10.1155/2015/356893 CrossRefPubMedPubMedCentral

60.

Zhang CY, Yu MS, Li X, Zhang Z, Han CR, Yan B (2017) Overexpression of long non-coding RNA MEG3 suppresses breast cancer cell proliferation, invasion. and angiogenesis through AKT pathway Tumour Biol 39(6):1010428317701311. https://doi.org/10.1177/1010428317701311 CrossRefPubMed

61.

Liu J, Li Q, Zhang KS, Hu B, Niu X, Zhou SM, Li SG, Luo YP, Wang Y, Deng ZF (2017) Downregulation of the Long non-coding RNA Meg3 promotes angiogenesis after ischemic brain injury by activating notch signaling. Mol Neurobiol 54(10):8179–8190. https://doi.org/10.1007/s12035-016-0270-z CrossRefPubMed

62.

Ruan W, Zhao F, Zhao S, Zhang L, Shi L, Pang T (2018) Knockdown of long noncoding RNA MEG3 impairs VEGF-stimulated endothelial sprouting angiogenesis via modulating VEGFR2 expression in human umbilical vein endothelial cells. Gene 649:32–39. https://doi.org/10.1016/j.gene.2018.01.072 CrossRefPubMed

63.

He C, Yang W, Yang J, Ding J, Li S, Wu H, Zhou F, Jiang Y, Teng L, Yang J (2017) Long noncoding RNA MEG3 negatively regulates proliferation and angiogenesis in vascular endothelial cells. DNA Cell Biol 36(6):475–481. https://doi.org/10.1089/dna.2017.3682 CrossRefPubMed

64.

Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31(1):27–36. https://doi.org/10.1093/carcin/bgp220 CrossRefPubMed

65.

Cheung HH, Lee TL, Rennert OM, Chan WY (2009) DNA methylation of cancer genome. Birth Defects Res C Embryo Today 87(4):335–350. https://doi.org/10.1002/bdrc.20163 CrossRefPubMedPubMedCentral

66.

Deaton AM, Bird A (2011) CpG islands and the regulation of transcription. Genes Dev 25(10):1010–1022. https://doi.org/10.1101/gad.2037511 CrossRefPubMedPubMedCentral

67.

Delpu Y, Cordelier P, Cho WC, Torrisani J (2013) DNA methylation and cancer diagnosis. Int J Mol Sci 14(7):15029–15058. https://doi.org/10.3390/ijms140715029 CrossRefPubMedPubMedCentral

68.

Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, Swearingen B, Stratakis CA, Hedley-Whyte ET, Klibanski A (2008) Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 93(10):4119–4125. https://doi.org/10.1210/jc.2007-2633 CrossRefPubMedPubMedCentral

69.

Liu X, Gao Q, Li P, Zhao Q, Zhang J, Li J, Koseki H, Wong J (2013) UHRF1 targets DNMT1 for DNA methylation through cooperative binding of hemi-methylated DNA and methylated H3K9. Nat Commun 4:1563CrossRefPubMed

70.

Lu KH, Li W, Liu XH, Sun M, Zhang ML, Wu WQ, Xie WP, Hou YY (2013) Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer 13:461. https://doi.org/10.1186/1471-2407-13-461 CrossRefPubMedPubMedCentral

71.

Zhuo H, Tang J, Lin Z, Jiang R, Zhang X, Ji J, Wang P, Sun B (2016) The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma. Mol Carcinog 55(2):209–219. https://doi.org/10.1002/mc.22270 CrossRefPubMed

72.

Li J, Bian EB, He XJ, Ma CC, Zong G, Wang HL, Zhao B (2016) Epigenetic repression of long non-coding RNA MEG3 mediated by DNMT1 represses the p53 pathway in gliomas. Int J Oncol 48(2):723–733. https://doi.org/10.3892/ijo.2015.3285 CrossRefPubMed

73.

Yu B, Lv X, Su L, Li J, Yu Y, Gu Q, Yan M, Zhu Z, Liu B (2016) MiR-148a functions as a tumor suppressor by targeting CCK-BR via inactivating STAT3 and Akt in human gastric Cancer. PLoS One 11(8):e0158961. https://doi.org/10.1371/journal.pone.0158961 CrossRefPubMedPubMedCentral

74.

Shamma A, Suzuki M, Hayashi N, Kobayashi M, Sasaki N, Nishiuchi T, Doki Y, Okamoto T, Kohno S, Muranaka H, Kitajima S, Yamamoto K, Takahashi C (2013) ATM mediates pRB function to control DNMT1 protein stability and DNA methylation. Mol Cell Biol 33(16):3113–3124. https://doi.org/10.1128/MCB.01597-12 CrossRefPubMedPubMedCentral

75.

Kruer TL, Dougherty SM, Reynolds L, Long E, de Silva T, Lockwood WW, Clem BF (2016) Expression of the lncRNA maternally expressed gene 3 (MEG3) contributes to the control of lung Cancer cell proliferation by the Rb pathway. PLoS One 11(11):e0166363. https://doi.org/10.1371/journal.pone.0166363 CrossRefPubMedPubMedCentral

76.

Li Y, Ren M, Zhao Y, Lu X, Wang M, Hu J, Lu G, He S (2017) MicroRNA-26a inhibits proliferation and metastasis of human hepatocellular carcinoma by regulating DNMT3B-MEG3 axis. Oncol Rep 37(6):3527–3535. https://doi.org/10.3892/or.2017.5579 CrossRefPubMed

77.

Gao Y, Huang P, Zhang J (2017) Hypermethylation of MEG3 promoter correlates with inactivation of MEG3 and poor prognosis in patients with retinoblastoma. J Transl Med 15(1):268. https://doi.org/10.1186/s12967-017-1372-8 CrossRefPubMedPubMedCentral

78.

Polyak K (2011) Heterogeneity in breast cancer. J Clin Invest 121(10):3786–3788. https://doi.org/10.1172/JCI60534 CrossRefPubMedPubMedCentral

79.

Padua Alves C, Fonseca AS, Muys BR, de Barros ELBR, Burger MC, de Souza JE, Valente V, Zago MA, Silva WA Jr (2013) Brief report: the lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines. Stem Cells 31(12):2827–2832. https://doi.org/10.1002/stem.1547 CrossRefPubMed

80.

Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y, Zhao L, Zhang Y, Huang B, Lu J (2014) LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis 5:e1287. https://doi.org/10.1038/cddis.2014.249 CrossRefPubMedPubMedCentral

81.

Li H, Zhu L, Xu L, Qin K, Liu C, Yu Y, Su D, Wu K, Sheng Y (2017) Long noncoding RNA linc00617 exhibits oncogenic activity in breast cancer. Mol Carcinog 56(1):3–17. https://doi.org/10.1002/mc.22338 CrossRefPubMed

82.

Shahryari A, Jazi MS, Samaei NM, Mowla SJ (2015) Long non-coding RNA SOX2OT: expression signature, splicing patterns, and emerging roles in pluripotency and tumorigenesis. Front Genet 6:196. https://doi.org/10.3389/fgene.2015.00196 CrossRefPubMedPubMedCentral

83.

Redis RS, Sieuwerts AM, Look MP, Tudoran O, Ivan C, Spizzo R, Zhang X, de Weerd V, Shimizu M, Ling H, Buiga R, Pop V, Irimie A, Fodde R, Bedrosian I, Martens JW, Foekens JA, Berindan-Neagoe I, Calin GA (2013) CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget 4(10):1748–1762. https://doi.org/10.18632/oncotarget.1292 CrossRefPubMedPubMedCentral

84.

Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT (2009) GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 28(2):195–208. https://doi.org/10.1038/onc.2008.373 CrossRefPubMed

85.

Zhao Z, Chen C, Liu Y, Wu C (2014) 17beta-estradiol treatment inhibits breast cell proliferation, migration and invasion by decreasing MALAT-1 RNA level. Biochem Biophys Res Commun 445(2):388–393. https://doi.org/10.1016/j.bbrc.2014.02.006 CrossRefPubMed

86.

Zhang JJ, Guo SH, Jia BQ (2016) Down-regulation of long non-coding RNA MEG3 serves as an unfavorable risk factor for survival of patients with breast cancer. Eur Rev Med Pharmacol Sci 20(24):5143–5147PubMed

87.

Sun L, Li Y, Yang B (2016) Downregulated long non-coding RNA MEG3 in breast cancer regulates proliferation, migration and invasion by depending on p53's transcriptional activity. Biochem Biophys Res Commun 478(1):323–329. https://doi.org/10.1016/j.bbrc.2016.05.031 CrossRefPubMed

88.

Zhang W, Shi S, Jiang J, Li X, Lu H, Ren F (2017) LncRNA MEG3 inhibits cell epithelial-mesenchymal transition by sponging miR-421 targeting E-cadherin in breast cancer. Biomed Pharmacother 91:312–319. https://doi.org/10.1016/j.biopha.2017.04.085 CrossRefPubMed

89.

Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, Mitra S, Mohammed A, James AR, Hoberg E, Moustakas A, Gyllensten U, Jones SJ, Gustafsson CM, Sims AH, Westerlund F, Gorab E, Kanduri C (2015) MEG3 long noncoding RNA regulates the TGF-beta pathway genes through formation of RNA-DNA triplex structures. Nat Commun 6:7743. https://doi.org/10.1038/ncomms8743 CrossRefPubMed

90.

Laursen L (2014) A preventable cancer. Nature 516(7529):S2–S3. https://doi.org/10.1038/516S2a CrossRefPubMed

91.

Li T, Zheng Q, An J, Wu M, Li H, Gui X, Pu H, Lu D (2016) SET1A cooperates with CUDR to promote liver Cancer growth and hepatocyte-like stem cell malignant transformation epigenetically. Mol Ther 24(2):261–275. https://doi.org/10.1038/mt.2015.208 CrossRefPubMedPubMedCentral

92.

Li H, An J, Wu M, Zheng Q, Gui X, Li T, Pu H, Lu D (2015) LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2. Oncotarget 6(29):27847–27864. https://doi.org/10.18632/oncotarget.4443 CrossRefPubMedPubMedCentral

93.

Wang Y, He L, Du Y, Zhu P, Huang G, Luo J, Yan X, Ye B, Li C, Xia P, Zhang G, Tian Y, Chen R, Fan Z (2015) The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell 16(4):413–425. https://doi.org/10.1016/j.stem.2015.03.003 CrossRefPubMed

94.

Wang X, Sun W, Shen W, Xia M, Chen C, Xiang D, Ning B, Cui X, Li H, Li X, Ding J, Wang H (2016) Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. J Hepatol 64(6):1283–1294. https://doi.org/10.1016/j.jhep.2016.01.019 CrossRefPubMed

95.

He JH, Han ZP, Liu JM, Zhou JB, Zou MX, Lv YB, Li YG, Cao MR (2017) Overexpression of Long non-coding RNA MEG3 inhibits proliferation of hepatocellular carcinoma Huh7 cells via negative modulation of miRNA-664. J Cell Biochem 118(11):3713–3721. https://doi.org/10.1002/jcb.26018 CrossRefPubMed

96.

Zheng Q, Lin Z, Xu J, Lu Y, Meng Q, Wang C, Yang Y, Xin X, Li X, Pu H (2018) Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting β-catenin by activating PKM2 and inactivating PTEN. Cell Death Dis 9(3):253CrossRefPubMedPubMedCentral

97.

He Y, Wu YT, Huang C, Meng XM, Ma TT, Wu BM, Xu FY, Zhang L, Lv XW, Li J (2014) Inhibitory effects of long noncoding RNA MEG3 on hepatic stellate cells activation and liver fibrogenesis. Biochim Biophys Acta 1842(11):2204–2215. https://doi.org/10.1016/j.bbadis.2014.08.015 CrossRefPubMed

98.

Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL (2014) Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomark Prev 23(10):1985–1996. https://doi.org/10.1158/1055-9965.EPI-14-0275 CrossRef

99.

Galasso M, Dama P, Previati M, Sandhu S, Palatini J, Coppola V, Warner S, Sana ME, Zanella R, Abujarour R, Desponts C, Teitell MA, Garzon R, Calin G, Croce CM, Volinia S (2014) A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma. Genome Med 6(10):76. https://doi.org/10.1186/s13073-014-0076-4 CrossRefPubMedPubMedCentral

100.

Ellis BC, Molloy PL, Graham LD (2012) CRNDE: a Long non-coding RNA involved in CanceR, neurobiology, and DEvelopment. Front Genet 3:270. https://doi.org/10.3389/fgene.2012.00270 CrossRefPubMedPubMedCentral

101.

Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J, Chen L, Xi Z, Teng H, Wang Z, Li Z, Liu Y (2015) Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Cancer Lett 359(1):75–86. https://doi.org/10.1016/j.canlet.2014.12.051 CrossRefPubMed

102.

Wang P, Ren Z, Sun P (2012) Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J Cell Biochem 113(6):1868–1874. https://doi.org/10.1002/jcb.24055 CrossRefPubMed

103.

Shang S, Hua F, Hu ZW (2017) The regulation of beta-catenin activity and function in cancer: therapeutic opportunities. Oncotarget 8(20):33972–33989. https://doi.org/10.18632/oncotarget.15687 CrossRefPubMedPubMedCentral

104.

Gong X, Huang M (2017) Long non-coding RNA MEG3 promotes the proliferation of glioma cells through targeting Wnt/beta-catenin signal pathway. Cancer Gene Ther 24(9):381–385. https://doi.org/10.1038/cgt.2017.32 CrossRefPubMed

105.

Qin N, Tong GF, Sun LW, Xu XL (2017) Long noncoding RNA MEG3 suppresses glioma cell proliferation, migration, and invasion by acting as a competing endogenous RNA of miR-19a. Oncol Res 25(9):1471–1478. https://doi.org/10.3727/096504017X14886689179993 CrossRefPubMedPubMedCentral

106.

Zhang L, Liang X, Li Y (2017) Long non-coding RNA MEG3 inhibits cell growth of gliomas by targeting miR-93 and inactivating PI3K/AKT pathway. Oncol Rep 38(4):2408–2416. https://doi.org/10.3892/or.2017.5871 CrossRefPubMed

107.

Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F (2017) Global patterns and trends in colorectal cancer incidence and mortality. Gut 66(4):683–691. https://doi.org/10.1136/gutjnl-2015-310912 CrossRefPubMed

108.

Zhang Z, Zhou C, Chang Y, Zhang Z, Hu Y, Zhang F, Lu Y, Zheng L, Zhang W, Li X, Li X (2016) Long non-coding RNA CASC11 interacts with hnRNP-K and activates the WNT/beta-catenin pathway to promote growth and metastasis in colorectal cancer. Cancer Lett 376(1):62–73. https://doi.org/10.1016/j.canlet.2016.03.022 CrossRefPubMed

109.

Sun L, Jiang C, Xu C, Xue H, Zhou H, Gu L, Liu Y, Xu Q (2017) Down-regulation of long non-coding RNA RP11-708H21.4 is associated with poor prognosis for colorectal cancer and promotes tumorigenesis through regulating AKT/mTOR pathway. Oncotarget 8(17):27929–27942. https://doi.org/10.18632/oncotarget.15846 CrossRefPubMedPubMedCentral

110.

Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, Yu ZW, Jia YH, Bai XF, Li L, Liu YL, Cui BB (2017) The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/beta-catenin signaling. Mol Cancer 16(1):9. https://doi.org/10.1186/s12943-017-0583-1 CrossRefPubMedPubMedCentral

111.

Menigatti M, Staiano T, Manser CN, Bauerfeind P, Komljenovic A, Robinson M, Jiricny J, Buffoli F, Marra G (2013) Epigenetic silencing of monoallelically methylated miRNA loci in precancerous colorectal lesions. Oncogenesis 2:e56. https://doi.org/10.1038/oncsis.2013.21 CrossRefPubMedPubMedCentral

112.

Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, Zhang L, Xiao LJ, Wan DC, Zhang JF, Waye MM (2015) The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget 6(26):22513–22525. https://doi.org/10.18632/oncotarget.4154 CrossRefPubMedPubMedCentral

113.

Qi P, Xu MD, Ni SJ, Shen XH, Wei P, Huang D, Tan C, Sheng WQ, Zhou XY, Du X (2015) Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients. Mol Carcinog 54(9):742–750. https://doi.org/10.1002/mc.22137 CrossRefPubMed

114.

Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, Wu F, Mo YY (2013) LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res 41(9):4976–4987. https://doi.org/10.1093/nar/gkt182 CrossRefPubMedPubMedCentral

115.

Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, Guo RH (2015) Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol 36(6):4851–4859. https://doi.org/10.1007/s13277-015-3139-2 CrossRefPubMed

116.

Zhu Y, Chen P, Gao Y, Ta N, Zhang Y, Cai J, Zhao Y, Liu S, Zheng J (2018) MEG3 activated by vitamin D inhibits colorectal Cancer cells proliferation and migration via regulating Clusterin. EBioMedicine 30:148–157. https://doi.org/10.1016/j.ebiom.2018.03.032 CrossRefPubMedPubMedCentral

117.

Li L, Shang J, Zhang Y, Liu S, Peng Y, Zhou Z, Pan H, Wang X, Chen L, Zhao Q (2017) MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis. Oncol Rep 38(3):1383–1392. https://doi.org/10.3892/or.2017.5828 CrossRefPubMedPubMedCentral

118.

Cao X, Zhuang S, Hu Y, Xi L, Deng L, Sheng H, Shen W (2016) Associations between polymorphisms of long non-coding RNA MEG3 and risk of colorectal cancer in Chinese. Oncotarget 7(14):19054–19059. https://doi.org/10.18632/oncotarget.7764 CrossRefPubMedPubMedCentral

119.

Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M (2011) Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378(9801):1461–1484. https://doi.org/10.1016/S0140-6736(11)61351-2 CrossRefPubMed

120.

Huang L, Liao LM, Liu AW, Wu JB, Cheng XL, Lin JX, Zheng M (2014) Overexpression of long noncoding RNA HOTAIR predicts a poor prognosis in patients with cervical cancer. Arch Gynecol Obstet 290(4):717–723. https://doi.org/10.1007/s00404-014-3236-2 CrossRefPubMed

121.

Cao S, Liu W, Li F, Zhao W, Qin C (2014) Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer. Int J Clin Exp Pathol 7(10):6776–6783PubMedPubMedCentral

122.

Liao LM, Sun XY, Liu AW, Wu JB, Cheng XL, Lin JX, Zheng M, Huang L (2014) Low expression of long noncoding XLOC_010588 indicates a poor prognosis and promotes proliferation through upregulation of c-Myc in cervical cancer. Gynecol Oncol 133(3):616–623. https://doi.org/10.1016/j.ygyno.2014.03.555 CrossRefPubMed

123.

Jiang S, Wang HL, Yang J (2015) Low expression of long non-coding RNA LET inhibits carcinogenesis of cervical cancer. Int J Clin Exp Pathol 8(1):806–811PubMedPubMedCentral

124.

Yang M, Zhai X, Xia B, Wang Y, Lou G (2015) Long noncoding RNA CCHE1 promotes cervical cancer cell proliferation via upregulating PCNA. Tumour Biol 36(10):7615–7622. https://doi.org/10.1007/s13277-015-3465-4 CrossRefPubMed

125.

Qin R, Chen Z, Ding Y, Hao J, Hu J, Guo F (2013) Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma 60(5):486–492CrossRefPubMed

126.

Zhang J, Yao T, Wang Y, Yu J, Liu Y, Lin Z (2016) Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biol Ther 17(1):104–113. https://doi.org/10.1080/15384047.2015.1108496 CrossRefPubMed

127.

Zhang J, Lin Z, Gao Y, Yao T (2017) Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer. J Exp Clin Cancer Res 36(1):5. https://doi.org/10.1186/s13046-016-0472-2 CrossRefPubMedPubMedCentral

128.

Zhang J, Yao T, Lin Z, Gao Y (2017) Aberrant methylation of MEG3 functions as a potential plasma-based biomarker for cervical Cancer. Sci Rep 7(1):6271. https://doi.org/10.1038/s41598-017-06502-7 CrossRefPubMedPubMedCentral

129.

Wang X, Wang Z, Wang J, Wang Y, Liu L, Xu X (2017) LncRNA MEG3 has anti-activity effects of cervical cancer. Biomed Pharmacother 94:636–643. https://doi.org/10.1016/j.biopha.2017.07.056 CrossRefPubMed

130.

Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global Cancer incidence and mortality rates and trends--An update. Cancer Epidemiol Biomark Prev 25(1):16–27. https://doi.org/10.1158/1055-9965.EPI-15-0578 CrossRef

131.

Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D, Xie M, Xu L, De W, Wang Z, Wang J (2016) LncRNA HOXA11-AS promotes proliferation and invasion of gastric Cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res 76(21):6299–6310. https://doi.org/10.1158/0008-5472.CAN-16-0356 CrossRefPubMed

132.

Xu TP, Huang MD, Xia R, Liu XX, Sun M, Yin L, Chen WM, Han L, Zhang EB, Kong R, De W, Shu YQ (2014) Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression. J Hematol Oncol 7:63. https://doi.org/10.1186/s13045-014-0063-7 CrossRefPubMedPubMedCentral

133.

Sun TT, He J, Liang Q, Ren LL, Yan TT, Yu TC, Tang JY, Bao YJ, Hu Y, Lin Y, Sun D, Chen YX, Hong J, Chen H, Zou W, Fang JY (2016) LncRNA GClnc1 promotes gastric carcinogenesis and may act as a modular scaffold of WDR5 and KAT2A complexes to specify the histone modification pattern. Cancer Discov 6(7):784–801. https://doi.org/10.1158/2159-8290.CD-15-0921 CrossRefPubMed

134.

Wu SW, Hao YP, Qiu JH, Zhang DB, Yu CG, Li WH (2017) High expression of long non-coding RNA CCAT2 indicates poor prognosis of gastric cancer and promotes cell proliferation and invasion. Minerva Med 108(4):317–323. https://doi.org/10.23736/S0026-4806.17.04703-6 CrossRefPubMed

135.

Hu Y, Ma Z, He Y, Liu W, Su Y, Tang Z (2017) LncRNA-SNHG1 contributes to gastric cancer cell proliferation by regulating DNMT1. Biochem Biophys Res Commun 491(4):926–931. https://doi.org/10.1016/j.bbrc.2017.07.137 CrossRefPubMed

136.

Yan J, Guo X, Xia J, Shan T, Gu C, Liang Z, Zhao W, Jin S (2014) MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1. Med Oncol 31(3):879. https://doi.org/10.1007/s12032-014-0879-6 CrossRefPubMed

137.

Wei GH, Wang X (2017) lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci 21(17):3850–3856PubMed

138.

Sun M, Xia R, Jin F, Xu T, Liu Z, De W, Liu X (2014) Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 35(2):1065–1073. https://doi.org/10.1007/s13277-013-1142-z CrossRefPubMed

139.

Peng W, Si S, Zhang Q, Li C, Zhao F, Wang F, Yu J, Ma R (2015) Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. J Exp Clin Cancer Res 34:79. https://doi.org/10.1186/s13046-015-0197-7 CrossRefPubMedPubMedCentral

140.

Wong MCS, Lao XQ, Ho KF, Goggins WB, Tse SLA (2017) Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep 7(1):14300. https://doi.org/10.1038/s41598-017-14513-7 CrossRefPubMedPubMedCentral

141.

Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32(4):605–644. https://doi.org/10.1016/j.ccm.2011.09.001 CrossRef

142.

Zhang L, Zhou XF, Pan GF, Zhao JP (2014) Enhanced expression of long non-coding RNA ZXF1 promoted the invasion and metastasis in lung adenocarcinoma. Biomed Pharmacother 68(4):401–407. https://doi.org/10.1016/j.biopha.2014.03.001 CrossRefPubMed

143.

Whiteside EJ, Seim I, Pauli JP, O'Keeffe AJ, Thomas PB, Carter SL, Walpole CM, Fung JN, Josh P, Herington AC, Chopin LK (2013) Identification of a long non-coding RNA gene, growth hormone secretagogue receptor opposite strand, which stimulates cell migration in non-small cell lung cancer cell lines. Int J Oncol 43(2):566–574. https://doi.org/10.3892/ijo.2013.1969 CrossRefPubMed

144.

Nie FQ, Zhu Q, Xu TP, Zou YF, Xie M, Sun M, Xia R, Lu KH (2014) Long non-coding RNA MVIH indicates a poor prognosis for non-small cell lung cancer and promotes cell proliferation and invasion. Tumour Biol 35(8):7587–7594. https://doi.org/10.1007/s13277-014-2009-7 CrossRefPubMed

145.

Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W, De W, Wang Z, Wang R (2013) The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PLoS One 8(10):e77293. https://doi.org/10.1371/journal.pone.0077293 CrossRefPubMedPubMedCentral

146.

Qiu M, Xu Y, Yang X, Wang J, Hu J, Xu L, Yin R (2014) CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer. Tumour Biol 35(6):5375–5380. https://doi.org/10.1007/s13277-014-1700-z CrossRefPubMed

147.

Sun M, Liu XH, Lu KH, Nie FQ, Xia R, Kong R, Yang JS, Xu TP, Liu YW, Zou YF, Lu BB, Yin R, Zhang EB, Xu L, De W, Wang ZX (2014) EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition. Cell Death Dis 5:e1298. https://doi.org/10.1038/cddis.2014.256 CrossRefPubMedPubMedCentral

148.

Song H, Li Y, Lee J, Schwartz AL, Bu G (2009) Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res 69(3):879–886. https://doi.org/10.1158/0008-5472.CAN-08-3379 CrossRefPubMedPubMedCentral

149.

Huang XY, Shi GM, Devbhandari RP, Ke AW, Wang Y, Wang XY, Wang Z, Shi YH, Xiao YS, Ding ZB, Dai Z, Xu Y, Jia WP, Tang ZY, Fan J, Zhou J (2012) Low level of low-density lipoprotein receptor-related protein 1 predicts an unfavorable prognosis of hepatocellular carcinoma after curative resection. PLoS One 7(3):e32775. https://doi.org/10.1371/journal.pone.0032775 CrossRefPubMedPubMedCentral

150.

Terashima M, Tange S, Ishimura A, Suzuki T (2017) MEG3 Long noncoding RNA contributes to the epigenetic regulation of epithelial-mesenchymal transition in lung Cancer cell lines. J Biol Chem 292(1):82–99. https://doi.org/10.1074/jbc.M116.750950 CrossRefPubMed

151.

Xia Y, He Z, Liu B, Wang P, Chen Y (2015) Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/beta-catenin signaling pathway. Mol Med Rep 12(3):4530–4537. https://doi.org/10.3892/mmr.2015.3897 CrossRefPubMed

152.

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. https://doi.org/10.3322/caac.21166 CrossRefPubMed

153.

Fu Y, Biglia N, Wang Z, Shen Y, Risch HA, Lu L, Canuto EM, Jia W, Katsaros D, Yu H (2016) Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer. Gynecol Oncol 143(3):642–649. https://doi.org/10.1016/j.ygyno.2016.09.021 CrossRefPubMedPubMedCentral

154.

Chen Q, Liu X, Xu L, Wang Y, Wang S, Li Q, Huang Y, Liu T (2016) Long non-coding RNA BACE1-AS is a novel target for anisomycin-mediated suppression of ovarian cancer stem cell proliferation and invasion. Oncol Rep 35(4):1916–1924. https://doi.org/10.3892/or.2016.4571 CrossRefPubMed

155.

Wu DI, Wang T, Ren C, Liu L, Kong D, Jin X, Li X, Zhang G (2016) Downregulation of BC200 in ovarian cancer contributes to cancer cell proliferation and chemoresistance to carboplatin. Oncol Lett 11(2):1189–1194. https://doi.org/10.3892/ol.2015.3983 CrossRefPubMed

156.

Szafron LM, Balcerak A, Grzybowska EA, Pienkowska-Grela B, Podgorska A, Zub R, Olbryt M, Pamula-Pilat J, Lisowska KM, Grzybowska E, Rubel T, Dansonka-Mieszkowska A, Konopka B, Kulesza M, Lukasik M, Kupryjanczyk J (2015) The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients. Oncotarget 6(41):43897–43910. https://doi.org/10.18632/oncotarget.6016 CrossRefPubMedPubMedCentral

157.

Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L (2014) A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell 26(3):344–357. https://doi.org/10.1016/j.ccr.2014.07.009 CrossRefPubMedPubMedCentral

158.

Gao Y, Meng H, Liu S, Hu J, Zhang Y, Jiao T, Liu Y, Ou J, Wang D, Yao L, Liu S, Hui N (2015) LncRNA-HOST2 regulates cell biological behaviors in epithelial ovarian cancer through a mechanism involving microRNA let-7b. Hum Mol Genet 24(3):841–852. https://doi.org/10.1093/hmg/ddu502 CrossRefPubMed

159.

Sheng X, Li J, Yang L, Chen Z, Zhao Q, Tan L, Zhou Y, Li J (2014) Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer. Oncol Rep 32(1):277–285. https://doi.org/10.3892/or.2014.3208 CrossRefPubMed

160.

Xiu YL, Sun KX, Chen X, Chen S, Zhao Y, Guo QG, Zong ZH (2017) Upregulation of the lncRNA Meg3 induces autophagy to inhibit tumorigenesis and progression of epithelial ovarian carcinoma by regulating activity of ATG3. Oncotarget 8(19):31714–31725. https://doi.org/10.18632/oncotarget.15955 CrossRefPubMedPubMedCentral

161.

Moore DD, Luu HH (2014) Osteosarcoma. Cancer Treat Res 162:65–92. https://doi.org/10.1007/978-3-319-07323-1_4 CrossRefPubMed

162.

Wang B, Su Y, Yang Q, Lv D, Zhang W, Tang K, Wang H, Zhang R, Liu Y (2015) Overexpression of Long non-coding RNA HOTAIR promotes tumor growth and metastasis in human osteosarcoma. Mol Cell 38(5):432–440. https://doi.org/10.14348/molcells.2015.2327 CrossRef

163.

Luo W, He H, Xiao W, Liu Q, Deng Z, Lu Y, Wang Q, Zheng Q, Li Y (2016) MALAT1 promotes osteosarcoma development by targeting TGFA via MIR376A. Oncotarget 7(34):54733–54743. https://doi.org/10.18632/oncotarget.10752 CrossRefPubMedPubMedCentral

164.

Chan LH, Wang W, Yeung W, Deng Y, Yuan P, Mak KK (2014) Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene 33(40):4857–4866. https://doi.org/10.1038/onc.2013.433 CrossRefPubMed

165.

Ruan W, Wang P, Feng S, Xue Y, Li Y (2016) Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes cell proliferation and migration by upregulating angiomotin gene expression in human osteosarcoma cells. Tumour Biol 37(3):4065–4073. https://doi.org/10.1007/s13277-015-4256-7 CrossRefPubMed

166.

Yin Z, Ding H, He E, Chen J, Li M (2016) Overexpression of long non-coding RNA MFI2 promotes cell proliferation and suppresses apoptosis in human osteosarcoma. Oncol Rep 36(4):2033–2040. https://doi.org/10.3892/or.2016.5013 CrossRefPubMed

167.

Tian ZZ, Guo XJ, Zhao YM, Fang Y (2015) Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma. Int J Clin Exp Pathol 8(11):15138–15142PubMedPubMedCentral

168.

Sahin Y, Altan Z, Arman K, Bozgeyik E, Koruk Ozer M, Arslan A (2017) Inhibition of miR-664a interferes with the migration of osteosarcoma cells via modulation of MEG3. Biochem Biophys Res Commun 490(3):1100–1105. https://doi.org/10.1016/j.bbrc.2017.06.174 CrossRefPubMed

169.

Yu F, Geng W, Dong P, Huang Z, Zheng J (2018) LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212. Cell Death Dis 9(10):1014. https://doi.org/10.1038/s41419-018-1068-x CrossRefPubMedPubMedCentral

170.

Xue R, Li Y, Li X, Ma J, An C, Ma Z (2018) miR-185 affected the EMT, cell viability and proliferation via DNMT1/MEG3 pathway in TGF-beta1-induced renal fibrosis. Cell Biol Int. https://doi.org/10.1002/cbin.11046

171.

He H, Dai J, Zhuo R, Zhao J, Wang H, Sun F, Zhu Y, Xu D (2018) Study on the mechanism behind lncRNA MEG3 affecting clear cell renal cell carcinoma by regulating miR-7/RASL11B signaling. J Cell Physiol 233(12):9503–9515. https://doi.org/10.1002/jcp.26849 CrossRefPubMed

172.

Long J, Pi X (2018) lncRNA-MEG3 suppresses the proliferation and invasion of melanoma by regulating CYLD expression mediated by sponging miR-499-5p. Biomed Res Int 2018:2086564. https://doi.org/10.1155/2018/2086564 CrossRefPubMedPubMedCentral

173.

Li Z, Yang L, Liu X, Nie Z, Luo J (2018) Long noncoding RNA MEG3 inhibits proliferation of chronic myeloid leukemia cells by sponging microRNA21. Biomed Pharmacother 104:181–192. https://doi.org/10.1016/j.biopha.2018.05.047 CrossRefPubMed

174.

Xu J, Xu Y (2017) The lncRNA MEG3 downregulation leads to osteoarthritis progression via miR-16/SMAD7 axis. Cell Biosci 7:69. https://doi.org/10.1186/s13578-017-0195-x CrossRefPubMedPubMedCentral

175.

Li J, Zi Y, Wang W, Li Y (2018) Long noncoding RNA MEG3 inhibits cell proliferation and metastasis in chronic myeloid leukemia via targeting miR-184. Oncol Res 26(2):297–305. https://doi.org/10.3727/096504017X14980882803151 CrossRefPubMedCentral

176.

Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, Negrini M, Miotto E, Croce CM, Patel T (2011) microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 30(47):4750–4756. https://doi.org/10.1038/onc.2011.193 CrossRefPubMedPubMedCentral

177.

Guo W, Dong Z, Liu S, Qiao Y, Kuang G, Guo Y, Shen S, Liang J (2017) Promoter hypermethylation-mediated downregulation of miR-770 and its host gene MEG3, a long non-coding RNA, in the development of gastric cardia adenocarcinoma. Mol Carcinog 56(8):1924–1934. https://doi.org/10.1002/mc.22650 CrossRefPubMed

178.

Wang Y, Kong D (2018) Knockdown of lncRNA MEG3 inhibits viability, migration, and invasion and promotes apoptosis by sponging miR-127 in osteosarcoma cell. J Cell Biochem 119(1):669–679. https://doi.org/10.1002/jcb.26230 CrossRefPubMed

179.

Wang H, Li H, Zhang L, Yang D (2018) Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis. Biomed Pharmacother 106:1607–1615. https://doi.org/10.1016/j.biopha.2018.07.131 CrossRefPubMed

180.

Wang P, Chen D, Ma H, Li Y (2017) LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. Onco Targets Ther 10:5137–5149. https://doi.org/10.2147/OTT.S146423 CrossRefPubMedPubMedCentral

181.

Liu Y, Yue P, Zhou T, Zhang F, Wang H, Chen X (2018) LncRNA MEG3 enhances (131)I sensitivity in thyroid carcinoma via sponging miR-182. Biomed Pharmacother 105:1232–1239. https://doi.org/10.1016/j.biopha.2018.06.087 CrossRefPubMed

182.

Zhang J, Liu J, Xu X, Li L (2017) Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer. Cancer Chemother Pharmacol 79(3):479–487. https://doi.org/10.1007/s00280-017-3238-4 CrossRefPubMed

At a glance: The STEP trials

Springer Medicine

MEG3: an Oncogenic Long Non-coding RNA in Different Cancers

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores

Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis

Thyroid Carcinoma Coexisting with Hashimoto’s Thyreoiditis: Clinicopathological and Molecular Characteristics Clue up Pathogenesis

Immunocytochemistry Based on a Cell-Type-Specific Aptamer for Rapid Immunostaining of Adenocarcinoma Cells in Clinical Serosal Fluids

Polymorphisms in Genes Related to Cervical Cancer in A Brazilian Population: A Case-Control Study

Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer